Targeting BATF: A new strategy for cancer immunotherapy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026-07 · 1881 (3) · 189579
DOI: 10.1016/j.bbcan.2026.189579 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026-07. Verfasst von Linyang Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM …. Hauptthemen laut MEDLINE: Basic-Leucine Zipper Transcription Factors, Immunotherapy, Neoplasms. Die Arbeit nennt 83 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunotherapy encompasses a variety of strategies for combating tumors, including the use of antibody drugs, cell transfer therapy, and tumor vaccines, but these approaches still face several challenges. Owing to advancements in single-cell sequencing technology, researchers have recently identified new therapeutic targets that enable T cells to penetrate tumor tissue more deeply and enhance their ability to attack tumor cells, thereby improving treatment outcomes. In this process, particularly under conditions of T cell exhaustion, the basic leucine zipper transcription factor ATF-like protein (BATF) plays a crucial role in the maturation and activity of T cells. BATF regulates the differentiation and function of T cells, thereby influencing their ability to combat tumor cells. Additionally, there is a positive feedback mechanism between BATF and PD-1 expression, which may also lead to T cells rapidly losing their ability to attack tumor cells. This review describes the latest advances in research on new targets for antitumour immunotherapy. It focuses on the role of BATF in the development and exhaustion of CD8+ T cells while summarizing the application of BATF as a new target in antitumor immunotherapy and the progress of related research. Our article highlights the importance of the BATF transcription factor in T cell development and exhaustion, outlines some of the challenges and contradictions encountered in BATF research as a new target in antitumor immunotherapy, and explains the potential causes of these contradictions. The aim of this review was to provide new insights and methods for antitumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine…
- Department of Respiratory and Critical Care, Xuanwu Hospital, Capital Medical University, Beijing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, L., Lin, X., Wang, Q., & Liu, S. (2026). Targeting BATF: A new strategy for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1881(3), 189579. https://doi.org/10.1016/j.bbcan.2026.189579
Vancouver
Li L, Lin X, Wang Q, Liu S. Targeting BATF: A new strategy for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026;1881(3):189579. doi:10.1016/j.bbcan.2026.189579
BibTeX
@article{Li2026,
author = {Li, Linyang and Lin, Xuwen and Wang, Qun and Liu, Sanhong},
title = {Targeting BATF: A new strategy for cancer immunotherapy},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
volume = {1881},
number = {3},
pages = {189579},
doi = {10.1016/j.bbcan.2026.189579}
}
EUVIMED